Related Experiment Video
Updated: Jul 29, 2026
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Polycythemia vera: diagnosis and treatment 2002
1Sylvester Cancer Center, Department of Medicine, University of Miami, FL, USA. nberlin@pol.net
Expert Review of Anticancer Therapy
|July 13, 2002
Summary
Polycythemia vera diagnosis is well-established, but treatment remains debated. This study suggests phosphorus-32 (32P) as a preferred therapy despite potential complications, acknowledging differing opinions among hematologists.
Area of Science:
- Hematology
- Oncology
Background:
- Polycythemia vera (PV) has been recognized since 1903, with established diagnostic criteria and clinical manifestations.
- Despite advances, consensus on optimal treatment strategies for PV remains elusive among hematologists.
- Evolving understanding of PV progression highlights risks of hemorrhagic/thrombotic complications and secondary leukemia with myelosuppressive treatments.
Purpose of the Study:
- To review the established knowledge of polycythemia vera.
- To discuss the challenges in selecting optimal treatment regimens for polycythemia vera.
- To propose criteria for comparing treatment efficacy and safety in polycythemia vera.
Main Methods:
- Review of historical and current clinical data on polycythemia vera.
- Analysis of treatment outcomes, focusing on complications such as thrombosis, hemorrhage, and acute leukemia.
- Development of suggested criteria for comparing different therapeutic approaches.
Main Results:
- Clinical, symptomatic, and hematological findings at diagnosis are well-characterized.
- Myelosuppressive therapies are associated with significant risks of thrombosis, hemorrhage, and acute leukemia.
- Phosphorus-32 (32P) is presented as a potential treatment of choice based on suggested comparative criteria.
Conclusions:
- Optimal treatment for polycythemia vera requires careful consideration of risks and benefits.
- Phosphorus-32 (32P) therapy is suggested as a leading option, though not universally accepted.
- Further discussion and consensus-building are needed regarding the management of polycythemia vera.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:26Varicose Veins II: Diagnostic Studies and Interprofessional Care
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...